In support, pretreatment absolute lymphocyte count (<600 cells/μl) was significantly associated with response to PD-1 inhibitors in patients with head and neck squamous cell carcinomas (n=34) (140). This evidence concerns the gene PDCD1 and head and neck squamous cell carcinoma.